Influência de combinações genéticas nos níveis de HDL-c em uma população do sul do Brasil

Abstract

Background: Low HDL-C levels are important predictors of coronary disease, the first cause of death worldwide. Many factors affect HDL-C levels, such as polymorphisms of genes encoding for key proteins of the reverse cholesterol transport pathway.

Association of SCARB1 Variants With Subclinical Atherosclerosis and Incident Cardiovascular Disease

“…The SCARB1 gene encodes scavenger receptor class B type I (SR-BI) protein, characterized as a high-density lipoprotein (HDL) receptor 1 . In humans, multiple studies have reported association of common SCARB1 single nucleotide polymorphisms (SNPs) with HDL cholesterol levels 2–5 . Existing studies also indicate the effects of SCARB1 variants on HDL levels may vary by gender 3, 6, 7 .…”

Consumo de alimentos fontes em antioxidantes por indiví­duos com doença cardiovascular

“…De acordo com a Tabela II, observa-se que os níveis de HDL-C apresentam-se inadequados de forma significativa, sendo 81,2% dos pacientes com o nível abaixo do recomendado. Diversos estudos científicos vêm comprovando que dentre as alterações do perfil lipídico, os níveis baixos de lipoproteína HDL-C são as alterações mais frequentes quando associados ao desenvolvimento de aterosclerose em pacientes com DAC [25][26][27]. Os baixos níveis de HDL-C, estão correlacionados com a ocorrência de disfunção endotelial, que posteriormente leva à DCV [28].…”

SR-B1, a Key Receptor Involved in the Progression of Cardiovascular Disease: A Perspective from Mice and Human Genetic Studies

“…Intron 5 variant was related to higher body mass index in women and lower TG levels in men [70]. Further population-base studies of SCARB1 gene polymorphisms established the involvement of these genetic variants in plasma lipoprotein profile [71,72], although several studies resulted in conflicting results [73,74] or failed to find an association [75,76]. These studies focused on different populations, including women and estrogen therapy [71], diabetics [72,75], different ethnic groups [77][78][79][80] individuals with familial hypercholesterolemia [51,81], and CVD patients [73][74][75][76][77][78][79][80][81][82][83].…”

“…Further population-base studies of SCARB1 gene polymorphisms established the involvement of these genetic variants in plasma lipoprotein profile [71,72], although several studies resulted in conflicting results [73,74] or failed to find an association [75,76]. These studies focused on different populations, including women and estrogen therapy [71], diabetics [72,75], different ethnic groups [77][78][79][80] individuals with familial hypercholesterolemia [51,81], and CVD patients [73][74][75][76][77][78][79][80][81][82][83]. Moreover, additional factors related to lipoprotein metabolism were evaluated in association with these genetic variants including the response to different diets [84,85] and pharmacological interventions [86,87].…”